8/11/2011 7:42:06 AM
Affecting nearly 36 million people worldwide, Alzheimer’s Disease (AD) is one of the most elusive chronic diseases in terms of diagnosis and treatment. The only definitive way to diagnose Alzheimer’s is through a brain autopsy or post-mortem. That may change because scientists at Durin Technologies and the University of Medicine and Dentistry of New Jersey have developed a test that can differentiate between the blood sera of those with AD and those in the non-demented control (NDC) group. The test uses a protein microarray to detect a group of 10 autoantibody biomarkers that the researchers showed could be used as specific and accurate indications of AD: It demonstrated a diagnostic sensitivity (detects positives correctly) of 96% and specificity (detects negatives correctly) of 92.5%.
comments powered by